{"analyses":[{"ciLowerLimit":"0.070","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","estimateComment":"Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab over Placebo.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1064","paramType":"Hazard Ratio (HR)","paramValue":"0.85","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.03","upperLimit":"61.63","value":"51.71"},{"groupId":"OG001","lowerLimit":"30.72","upperLimit":"48.76","value":"35.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"262"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to the date of death from any cause. For subjects that are alive, their survival time was censored at the date of last contact date (or \"last known alive date\"). Overall survival was censored at the date of randomization for subjects who were randomized but had no follow-up.","dispersionType":"Full Range","groups":[{"description":"Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.","id":"OG000","title":"Nivolumab"},{"description":"Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death (up to approximately 60 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}